Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL 250.
DIONOSIL AQUEOUS vs IOPAMIDOL-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent